Randomised Controlled Trial to Assess Whether Computed Tomography Cardiac Angiography Can Improve Invasive Coronary Angiography in Bypass Surgery Patients (BYPASS-CTCA)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03736018 |
Recruitment Status :
Active, not recruiting
First Posted : November 8, 2018
Last Update Posted : December 15, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Ischaemic Heart Disease Contrast-induced Nephropathy | Diagnostic Test: CTCA | Not Applicable |
The BYPASS-CTCA trial is a single-centre, randomised controlled trial, which plans to recruit 688 patients who have had previous bypass grafts and require invasive coronary angiography over a period of 30 months.
Patients will be randomised to receive either computed tomography cardiac angiography (CTCA) prior to their invasive coronary angiogram, or invasive coronary angiography alone.
The primary endpoints will be the incidence of contrast induced nephropathy, the duration of the invasive coronary angiographic procedure and patient satisfaction. A number of secondary endpoints will also be looked at.
Findings from BYPASS-CTCA will potentially demonstrate that a CTCA prior to invasive coronary angiography in this cohort of patients reduces the incidence of contrast-induced kidney injury, the length of procedure and improves patients satisfaction. The results of this trial may influence future clinical practice guidelines in coronary artery bypass graft patients undergoing invasive coronary procedures.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 688 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | A Randomised Controlled Trial Assessing the Value of Computed Tomography Cardiac Angiography in Improving Patient Satisfaction and Reducing Contrast Load, Procedural Duration and Complications in Patients Who Had Previous Bypass Operation Undergoing Invasive Coronary Angiography |
Actual Study Start Date : | November 15, 2018 |
Actual Primary Completion Date : | August 30, 2022 |
Estimated Study Completion Date : | September 30, 2023 |
Arm | Intervention/treatment |
---|---|
Active Comparator: CTCA + ICA
Computed Tomography Cardiac Angiography (CTCA) performed prior to invasive coronary angiogram (ICA).
|
Diagnostic Test: CTCA
Computed Tomography Cardiac angiography (CTCA) performed prior to invasive coronary angiogram (ICA).
Other Name: Computed Tomography Cardiac angiography |
No Intervention: ICA only
Invasive coronary angiogram (ICA) performed only.
|
- Procedural duration [ Time Frame: Interval between administration of local anaesthesia for obtaining vascular access and removal of the last catheter ]Length of invasive coronary angiogram
- Incidence of Contrast Induced Nephropathy [ Time Frame: 48-72hours ]Defined by Kidney Disease: Improving Global outcomes (KDIGO) criteria
- Patient satisfaction [ Time Frame: 4-6hours ]Patient satisfaction measured by validated questionnaire
- Contrast amount [ Time Frame: From time of arterial sheath insertion to removal of arterial catheters ]Contrast amount (mls) administered during invasive coronary angiogram
- Radiation exposure [ Time Frame: From time of arterial sheath insertion to removal of arterial catheters ]Radiation exposure (mSv) during invasive coronary angiogram
- Angiography related complications [ Time Frame: 4-6hours ]Angiography related complications (coronary or aortic dissection, stroke, bleeding, vascular access complications)
- Radial access rate [ Time Frame: From time of randomisation to end of invasive coronary angiogram procedure ]Radial access rates during invasive coronary angiogram
- Catheters used [ Time Frame: From time of arterial sheath insertion to removal of arterial catheters ]Number of catheters used during invasive coronary angiogram
- Computed Tomography Cardiac Angiography accuracy [ Time Frame: From time of randomisation to end of invasive coronary angiogram procedure ]Accuracy of the Computed Tomography Cardiac Angiography scan for detecting graft patency
- Number of grafts not identified [ Time Frame: From time of arterial sheath insertion to removal of arterial catheters ]Number of grafts not identified during invasive coronary angiogram
- Cost effectiveness of computed tomography cardiac angiography [ Time Frame: 12 months ]Incremental Cost Effectiveness Ratio (ICER)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients undergoing invasive coronary angiogram +/- percutaneous coronary Intervention
- Previous Coronary Artery Bypass Grafting (CABG)
- Aged ≥18
- Patients able and willing to give their written informed consent.
Exclusion Criteria:
- Subjects presenting with ST elevation myocardial infarction, cardiogenic shock (systolic blood pressure <80 mmHg for >30 minutes, or requiring inotropes or emergency intra aortic balloon pump for hypotension treatment) or cardiopulmonary resuscitation.
- Subjects with eGFR <20ml/min or on renal replacement therapy.
- Current life-threatening condition other than vascular disease that may prevent a subject completing the study.
- Clinical instability including cardiogenic shock, hypotension (low blood pressure-systolic blood pressure less than 90 mmHg), sustained ventricular or atrial arrhythmia requiring intravenous medications.
- Inability to tolerate beta-blockers, including those with chronic obstructive pulmonary disease or asthma, complete heart block, second-degree atrioventricular block
- Known contrast dye allergy.
- Pregnancy or unknown pregnancy status.
- Patients considered unsuitable to participate by the research team (e.g., due to medical reasons, laboratory abnormalities, or subject's unwillingness to comply with all study related procedures).
- Inability or refusal to provide informed consent.
- Any inclusion criteria not met

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03736018
United Kingdom | |
Barts Health NHS Trust | |
London, United Kingdom |
Principal Investigator: | Daniel Jones, MRCP, PhD | Queen Mary University of London |
Responsible Party: | Queen Mary University of London |
ClinicalTrials.gov Identifier: | NCT03736018 |
Other Study ID Numbers: |
Reda 012466 |
First Posted: | November 8, 2018 Key Record Dates |
Last Update Posted: | December 15, 2022 |
Last Verified: | December 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Trial protocol to be published |
Supporting Materials: |
Study Protocol |
Time Frame: | Late 2018 |
Access Criteria: | Freely available via journal |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Coronary Artery Bypass Grafts Computed Tomography Cardiac Angiography Invasive Coronary Angiogram |
Heart Diseases Myocardial Ischemia Coronary Artery Disease Cardiovascular Diseases |
Vascular Diseases Coronary Disease Arteriosclerosis Arterial Occlusive Diseases |